TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14965849

Group type: EXPERIMENTAL
Intervention: Telephone Intervention‐‐Problem Solving (TIPS) with face-to-face meetings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone Intervention‐‐Problem Solving (TIPS) without face-to-face meetings (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone Intervention‐‐Problem Solving (TIPS)
Number of subjects: 0
Study: 11749950

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs), administered twice daily for 12 weeks or longer
Number of subjects: 0
Study: 9760605

Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and trabeculectomy (PEM/TRAB) with mitomycin-C
Number of subjects: 42

Group type: COMPARATOR
Intervention: Trabeculectomy (TRAB) with mitomycin-C
Number of subjects: 42
Study: 8139476

Group type: EXPERIMENTAL
Intervention: Tetrahydrolipstatin (THL)
Number of subjects: 17
Study: 2850891

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment 4-times a day for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment 4-times a day for 7 days
Number of subjects: 42
Study: 31856882

Group type: EXPERIMENTAL
Intervention: PACE 'Steps to Success' programme
Number of subjects: 37
Study: 28179074

Group type: EXPERIMENTAL
Intervention: Erroneous examples
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correct examples
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no examples)
Number of subjects: 36
Study: 26307903

Group type: EXPERIMENTAL
Intervention: Thrice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Twice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Thrice-daily and twice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162
Study: 23212456

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study: 21665223

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (400 mg) or ground dried fish (529 ± 109 mg)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 18290842

Group type: EXPERIMENTAL
Intervention: Dysport 420 units
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dysport 210 units
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 16494642

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Number of subjects: 0
Study: 15013270

Group type: EXPERIMENTAL
Intervention: Elective caesarean section under nitrous oxide general anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elective caesarean section under nitrous oxide general anesthesia (cord plasma)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal delivery (cord plasma)
Number of subjects: 50
Study: 10938448

Group type: EXPERIMENTAL
Intervention: Smoking ad libitum
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-hour abstinence prior to data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mid-to-late follicular (MLF) phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late luteal (LL) phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-hour abstinence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking ad libitum and 24-hour abstinence
Number of subjects: 0
Study: 8923071

Group type: EXPERIMENTAL
Intervention: Teicoplanin-coated catheters (T; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control catheters (C; n = 10)
Number of subjects: 20
Study: 1409487

Group type: COMPARATOR
Intervention: Three middle-school interventions adopted by Minnesota school districts as a result of the 1985 legislation.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minnesota legislative initiative for tobacco use prevention.
Number of subjects: 48
Study: 3002167

Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prochlorperazine (15 mg)
Number of subjects: 24
Study: 31274267

Group type: EXPERIMENTAL
Intervention: ANI group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SPI group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Postoperative cortisol levels
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Postoperative pain scores
Number of subjects: 72
Study: 28032481

Group type: EXPERIMENTAL
Intervention: SER100 (10 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26301645

Group type: EXPERIMENTAL
Intervention: NAC (N-acetylcysteine) with sustained sodium chloride regime (1 mL/kg/h for 12 hours before, during, and 6 hours after the procedure) and oral NAC at 1.2 g bid for 3 days (n = 185)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: SOB (sodium bicarbonate) with abbreviated SOB regime (3 mL/kg/h 1 hour before the procedure, and 1 mL/kg/h during and 6 hours after the procedure) (n = 182)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: COM (combination of abbreviated SOB regime and oral NAC) (n = 181)
Number of subjects: 548

Group type: COMPARATOR
Intervention: NAC
Number of subjects: 548

Group type: COMPARATOR
Intervention: COM
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: NAC, SOB, COM
Number of subjects: 548
Study: 24623848

Group type: EXPERIMENTAL
Intervention: Genetic variants reflecting higher vitamin E status (specifically SNP rs964184)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: SNP rs964184 among homozygous carriers of the minor allele
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: SNP rs11057830 in SCARB1
Number of subjects: 1025
Study: 22193935

Group type: EXPERIMENTAL
Intervention: Speed walking paced by a metronome (Group A₁)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Walking a known distance in a fixed time (Group A₂)
Number of subjects: 47
Study: 19508995

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of BMMNC (n = 41)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Saline (control group, n = 45)
Number of subjects: 86
Study: 16396971

Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin alfa (32.1 microg/week)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Subcutaneous darbepoetin alfa (34.1 microg/week)
Number of subjects: 71
Study: 14607958

Group type: EXPERIMENTAL
Intervention: C5a receptor antagonist (10 mg/kg/day peroral, 0.3 mg/kg/day s.c.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day s.c.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of C5a antagonist and prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colitis control (drug-free)
Number of subjects: 0
Study: 10917389

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Population model
Number of subjects: 30
Study: 8930228

Group type: EXPERIMENTAL
Intervention: 1500 mg/d CNA (ENDURACIN) for 2 months
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 2000 mg/d CNA for 2 months
Number of subjects: 89

Group type: COMPARATOR
Intervention: Diet alone (American Heart Association Step I Diet) for 8 weeks
Number of subjects: 89
Study: 1357453

Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg bolus followed by 3.2 mg/h intravenously for 72 hours)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1005
Study: 4054430

Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 10
Study: 30776253

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 15
Study: 29749688

Group type: EXPERIMENTAL
Intervention: Constraint‐induced aphasia therapy (CIAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stimulation aphasia therapy (SAT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CIAT followed by SAT (C1S2 group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SAT followed by CIAT (S1C2 group)
Number of subjects: 20
Study: 25833808

Group type: EXPERIMENTAL
Intervention: Problem-Solving Education (PSE) among mothers with non-avoidant coping
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-avoidant controls
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Problem-Solving Education (PSE) among mothers with avoidant coping
Number of subjects: 93

Group type: COMPARATOR
Intervention: Avoidant controls
Number of subjects: 93
Study: 25310146

Group type: EXPERIMENTAL
Intervention: IL1 beta gene polymorphisms SNP‐511
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: IL1 beta gene polymorphisms SNP+3953
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Genotype C‐511C
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Genotype C+3953C
Number of subjects: 115
Study: 22057730

Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 15

Group type: COMPARATOR
Intervention: 50 ml of water (control)
Number of subjects: 15
Study: 20730260

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: No ischemic preconditioning
Number of subjects: 40
Study: 18602083

Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise test on a cycle ergometer with breath-by-breath gas measurements and continuous heart rate monitoring
Number of subjects: 24

Group type: COMPARATOR
Intervention: Graded aerobic exercise test on a cycle ergometer
Number of subjects: 24
Study: 16052584

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (etanercept and infliximab)
Number of subjects: 353
Study: 12444542

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily, increased to 10 mg daily if necessary after 6 weeks)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg daily, increased to 60 mg daily if necessary after 6 weeks)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 222

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 222
Study: 10363563

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase II (NOS II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase I (NOS I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase III (NOS III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOS expression in clear-cell adenocarcinomas and serous-type adenocarcinomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOS expression in uterine squamous carcinomas and endometrial adenocarcinomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of NOS expression with patients' age or clinical stage
Number of subjects: 0
Study: 7561417

Group type: EXPERIMENTAL
Intervention: Elastic double-finger bandage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aluminium splint
Number of subjects: 0
Study: 1935151

Group type: EXPERIMENTAL
Intervention: Double lumen umbilical venous catheters
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single lumen umbilical venous catheters
Number of subjects: 43
Study: 7020194

Group type: EXPERIMENTAL
Intervention: Irradiation of the larynx and all neck nodes (T+N), tumor dose 5130 rad/6‐7 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Irradiation of the laryngeal portals only (T), tumor dose 5130 rad/5 weeks
Number of subjects: 152
Study: 31675636

Group type: EXPERIMENTAL
Intervention: Direct referral to Physical Activity Guidelines (PAGs) from a physician (REF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (CON) given a print copy of PAGs
Number of subjects: 91
Study: 30136445

Group type: EXPERIMENTAL
Intervention: dHACM
Number of subjects: 110

Group type: COMPARATOR
Intervention: no-dHACM
Number of subjects: 110
Study: 28693525

Group type: EXPERIMENTAL
Intervention: Facility-based peer support
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Standard of care under Option B+
Number of subjects: 1269
Study: 26540987

Group type: EXPERIMENTAL
Intervention: Standard medical therapies and autologous BM-MNC transplantation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard medical therapies
Number of subjects: 61
Study: 24263273

Group type: EXPERIMENTAL
Intervention: 0.3-millisecond ultrabrief-pulse ECT
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1-millisecond brief-pulse ECT
Number of subjects: 40
Study: 21170641

Group type: EXPERIMENTAL
Intervention: Calcium-fortified ice cream containing 96, 244, 459 or 676 mg calcium daily for 28 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Calcium-fortified ice cream (244 mg calcium preparation)
Number of subjects: 80
Study: 19366270

Group type: EXPERIMENTAL
Intervention: HairMax LaserComb
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 110
Study: 17435563

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30
Study: 12610326

Group type: EXPERIMENTAL
Intervention: Cisapride (prokinetic)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10509847

Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg QD
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg BID
Number of subjects: 792

Group type: COMPARATOR
Intervention: Penicillin V 10 mg/kg 4 times daily
Number of subjects: 792
Study: 8568623

Group type: EXPERIMENTAL
Intervention: Sublingual oxytocin (400 int. units / 684 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (1 int. unit / 1.71 micrograms)
Number of subjects: 6
Study: 1848716

Group type: EXPERIMENTAL
Intervention: Ethiodized poppy‐seed oil
Number of subjects: 398

Group type: COMPARATOR
Intervention: Water-soluble contrast media (Iohexol, Ioxaglate, Diatrizoate meglumine)
Number of subjects: 398
Study: 7006790

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU (9 mg/kg intravenously for five consecutive days) and CCNU (70 mg/m2 orally on the first day of each course).
Number of subjects: 152

Group type: COMPARATOR
Intervention: No chemotherapy (control group).
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU and CCNU.
Number of subjects: 152
Study: 31935388

Group type: EXPERIMENTAL
Intervention: Antenatal counseling and postpartum intrauterine device (PPIUD) insertion services
Number of subjects: 75293

Group type: EXPERIMENTAL
Intervention: Antenatal counseling
Number of subjects: 75293
Study: 31039164

Group type: EXPERIMENTAL
Intervention: Non-liposomal nano-sized glutathione (NLNG) 200mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28506979

Group type: EXPERIMENTAL
Intervention: Ezetimibe added to simvastatin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin-placebo
Number of subjects: 0
Study: 26610355

Group type: EXPERIMENTAL
Intervention: Non-technical skills coaching after each of 5 simulated operations
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self-reflection after each of 5 simulated operations (Control)
Number of subjects: 16
Study: 23222037

Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (INT-GSH)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional guided bibliotherapy (BIB-GSH)
Number of subjects: 155
Study: 21355446

Group type: EXPERIMENTAL
Intervention: New pharmaceutical equivalent tablet formulation containing 300 mg of TDF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Innovator product
Number of subjects: 40
Study: 19113000

Group type: EXPERIMENTAL
Intervention: Automated turning using an air-cell mattress
Number of subjects: 10

Group type: COMPARATOR
Intervention: Manual turning
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Automated turning
Number of subjects: 10
Study: 16957067

Group type: EXPERIMENTAL
Intervention: Cerebellar damage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive feedback‐driven motor adaptations
Number of subjects: 0
Study: 14990649

Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine
Number of subjects: 258
Study: 9893184

Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy with 7 preseasonal injections of molecular standardized allergens from grass and rye pollen
Number of subjects: 48
Study: 8751095

Group type: EXPERIMENTAL
Intervention: 25 micrograms TPA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Buffer solution (control)
Number of subjects: 10
Study: 2037323

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 54

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study: 7029275

Group type: EXPERIMENTAL
Intervention: 100 mg of vitamin E per kilogram of body weight per day
Number of subjects: 101
Study: 31707245

Group type: EXPERIMENTAL
Intervention: Self-compassion in BD group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Nonattachment to self in BD group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Self-compassion and depression severity in BD group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Nonattachment to self and depression severity in BD group
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Nonattachment to self and hypo/mania symptomology in BD group
Number of subjects: 302
Study: 31011868

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 4659 (L. reuteri) plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus L. reuteri/bid for 10 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo plus ciprofloxacin 400 mg/bid and metronidazole 500 mg/tid for 1 week, plus placebo/bid for 10 days
Number of subjects: 88
Study: 29078109

Group type: EXPERIMENTAL
Intervention: Oral health checklist intervention
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Standard care (no form)
Number of subjects: 1248
Study: 27464029

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 11
Study: 25274445

Group type: EXPERIMENTAL
Intervention: Bayesian modeling approach for flexible modeling of semicompeting risks data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extension of illness-death models with flexible random effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalization of shared frailty models
Number of subjects: 0
Study: 22312175

Group type: EXPERIMENTAL
Intervention: Loozit intervention with additional therapeutic contact
Number of subjects: 151

Group type: COMPARATOR
Intervention: Loozit intervention without additional therapeutic contact
Number of subjects: 151
Study: 20565984

Group type: EXPERIMENTAL
Intervention: Initiation of PD one week after catheter insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of PD two weeks after catheter insertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initiation of PD four weeks after catheter insertion
Number of subjects: 0
Study: 17345547

Group type: EXPERIMENTAL
Intervention: Minimally invasive total hip replacement (MIS group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transgluteal approach (standard group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both surgical groups
Number of subjects: 32
Study: 16249665

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 41-60)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 61-80)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (BIS 21-40)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonanesthetized subjects
Number of subjects: 48
Study: 11919404

Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard Heparin
Number of subjects: 32
Study: 10607234

Group type: EXPERIMENTAL
Intervention: Combined prednisolone/interferon‐alpha2b (IFN‐alpha2b) therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2b (IFN‐alpha2b) therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 7642417

Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiation therapy (cisplatin 30 mg/m2 for 3 days, etoposid 80 mg/m2 for 3 days, 5-fluorouracil 900 mg/m2 for 4 days, radiation therapy 2 Gy twice a day for 5 days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Simultaneous chemoradiation therapy
Number of subjects: 47
Study: 30569502

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 104
Study: 28527768

Group type: EXPERIMENTAL
Intervention: Mirage sirolimus‐eluting bioresorbable microfiber scaffold
Number of subjects: 60

Group type: COMPARATOR
Intervention: Absorb bioresorbable vascular scaffold
Number of subjects: 60
Study: 25241107

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g bolus followed by 2 g/hour infusion for up to 12 hours)
Number of subjects: 1259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and Placebo
Number of subjects: 1259
Study: 24968577

Group type: EXPERIMENTAL
Intervention: Anuloma-viloma
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Yogic asanas
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study: 21489770

Group type: EXPERIMENTAL
Intervention: 50% N₂O in oxygen and sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50% air in oxygen and sevoflurane
Number of subjects: 40
Study: 19264239

Group type: EXPERIMENTAL
Intervention: <2-h infusion of eptifibatide
Number of subjects: 624

Group type: COMPARATOR
Intervention: 18-h infusion of eptifibatide
Number of subjects: 624
Study: 17546553

Group type: EXPERIMENTAL
Intervention: Lepirudin (0.25 mg/kg b. w. bolus and 0.2 mg/kg b. w. added to the CPB priming)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin (400 U/kg b. w. bolus with protamine reversal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lepirudin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20